Avelumab Program Rollover Study

Inclusion Criteria: * Participants under enrollment and treatment in an avelumab clinical study under the sponsorship of EMD Serono Research \& Development Institute, Inc. / Merck KGaA, Darmstadt, Germany * Merck Serono Co., Ltd (Japan) * Participants currently enrolled in an avelumab parent study and are on active treatment with avelumab or in long-term survival follow-up after treatment * Participants on active treatment must agree to continue to use highly effective contraception (that is, methods with a failure rate of less than 1% per year) for both male and female participants if the risk of conception exists * Other protocol defined inclusion criteria could apply. Exclusion Criteria: * Participants who are pregnant or breastfeeding * Participants still on active treatment: Known hypersensitivity to any of the study intervention ingredients * Participant has been enrolled in the comparator arm of avelumab parent study * Participant has been withdrawn from avelumab parent study for any reason * Any other reason that, in the opinion of the Investigator, precludes the participant from participating in the study * Other protocol defined exclusion criteria could apply.